Phase 3 Oesophageal Cancer Trial, Recruiting NCT04513808 Sponsor: The Cleveland Clinic Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 3 Oesophageal Cancer Trial, Recruiting

NCT04513808
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with primary esophageal cancer that is believed to be contained within the esophagus and has not spread to other areas (generally referred to as Stage 1 to 3).
  • People who are scheduled to have esophageal cancer surgery with the goal of removing all the cancer.
  • People who are willing to sign a consent form and agree to be randomly assigned to one of two types of anaesthesia during surgery.

Who may not be able to join:

  • People who have previously had surgery for esophageal cancer, not counting diagnostic biopsies.
  • People who are younger than 18 or older than 85 years of age.
  • People whose overall health is classified by their medical team as severely compromised (known as ASA Physical Status 4 or higher — confirm with trial site).
  • People who have a medical reason why they cannot receive either of the two anaesthetic medicines used in this trial (propofol or sevoflurane).
  • People who have another cancer that their surgeon does not believe has been in long-term remission.
  • People who have a serious ongoing illness that their surgeon believes carries a 25% or greater risk of death within two years.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yuwei Oui, MD, Shahai Hospital

Phone: 216-870-2620

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
15 August 2020
Est. completion
1 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Recurrence-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov